A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of LEGALON SIL for the Treatment of HCV Recurrence in Stable Liver Transplanted Patients

Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of LEGALON SIL for the Treatment of HCV Recurrence in Stable Liver Transplanted Patients

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2015

At a glance

  • Drugs Silibinin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Rottapharm Madaus
  • Most Recent Events

    • 25 Apr 2013 Primary endpoint 'Viral-load' has been met.
    • 25 Apr 2013 Results presented at the 48th Annual Meeting of the European Association for the Study of the Liver.
    • 06 May 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top